Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: An in vivo study

Medical Science Monitor

Volumn 15, Issue 1, 2009, Pages

  Lv, Sheng Qing ^a   Zhang, Ke Bin ^a   Zhang, Eric E ^b   Gao, Fang You ^a   Yin, Chang Lin ^a   Huang, Chun Ji ^a   He, Jia Quan ^a   Yang, Hui ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

5 Fluorocytosine; 5 Fluorouracil; Antitumor efficiency; Cytosine deaminase; Gene therapy; Malignant gliomas

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; PLASMID DNA; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE THERAPY; TUMOR NECROSIS; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSINE DEAMINASE; DNA PRIMERS; ESCHERICHIA COLI; FLUCYTOSINE; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GENE THERAPY; GLIOMA; IMMUNOBLOTTING; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 58649083681     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Davis FG, Freels S, Grutsch J et al: Survival rates in patients with primary malignant brain tumors stratified by patients age and tumor histological type: an analysis base on Surveillance, Epidemiology and End Results (SEER) data, 1973-1991. J Neurosurg, 1988; 88: 1-10
2. Claus EB, Black PM: Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973-2001. Cancer, 2006; 106: 1358-63
3. Surawicz TS, Davis F, Freels S et al: Brain tumor survival: results from the National Cancer Data Base. J Neurooncol, 1998; 40: 151-60
4. Chang SM, Parney IF, Huang W et al: Glioma Outcomes Project Investigators: Patterns of care for adults with newly diagnosed malignant glioma. JAMA, 2005; 293: 557-64,615-17
5. Schneider SW, Ludwig T, Tatenhorst L et al: Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol, 2004; 107(3): 272-76
6. Bevin DK, Keles GE, Aldape K, Berger MS: Aggressive glial neoplasms. In: Batjer HH, Loftus CM. eds. Textbook of Neurological Surgery: Principles and Practice (Vol. 2). Philadelphia: Lippincott Williams & Wilkins, 2003; 1270-80
7. Rainov NG, Ren H: Gene therapy for human malignant brain tumors. Cancer J, 2003; 9: 180-88
8. Kirsch M, Strasser J, Allende R et al: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res, 1998; 58: 4654-59
9. Farquhar D, Pan BF, Sakurai M et al: Suicide gene therapy using E. coli β-galactosidase. Cancer Chemother Pharmacol, 2002; 50: 65-70
10. Riddle DS, Sanz L, Chong H et al: Tumor cell surface display of immunoglobulin heavy chain Fc by gene transfer as a means to mimic antibody therapy. Hum Gene Ther, 2005; 16: 830-44
11. Pau G, Cavaggioni A, Calvi P et al: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther, 1999; 6: 330-37
12. Yazawa K, Fisher WE, Brunicardi FC: Current progress in suicide gene therapy for cancer. World J Surg, 2002; 26: 783-89
13. Austin EA, Huber BE: A first step in development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol, 1993; 43: 380-87
14. Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M: Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol, 2001; 8: S5-S8
15. Yao B, He QM, Tian L et al: Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. Hum Gene Ther, 2005; 16: 1075-86
16. Fu GF, Lin XH, Han QW et al: RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol Ther, 2005; 4: 822-29
17. Lv SQ, Yang H, He JQ et al: Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro. Acta Biochim Biophys Sin, 2003; 35: 430-34
18. Nishiyama T, Kawamura Y, Kawamoto K et al: Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res 1985; 45: 1753-61
19. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA, 1992; 89: 33-37
20. Hirschowitz EA, Ohwada A, Pascal WR et al: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther, 1995; 6: 1055-63
21. Lan KH, Kanai F, Shiratori Y et al: In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res, 1997; 57: 4279-84
22. Kaliberov SA, Market JM, Gillespie GY et al: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Ther, 2007; 14: 1111-19
23. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY: Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental glioblastomas. Cancer Res, 2002; 62: 773-80
24. Meadows LM, Walther P, Ozer H: a-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. Seminars in Oncology, 1991; 18: 71-76
25. Al Safarjalani ON, Rais R, Shi J et al: Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uriding phosphorylase inhibitor. Cancer Chemother Pharmacol, 2006; 58: 692-98
26. Pirzada NA, Ali II, Dafer RM: Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000; 34(1): 35-38
27. Barba D, Hardin J, Gage FH: Thymidine kinase mediated killing of rat brain tumors. J Neurosurg, 1993; 79: 729-35
28. Hadaczek P, Mirek H, Berger MS, Bankiewicz K: Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J Neurosurg, 2005; 102: 328-35
29. Gardlik R, Palffy R, Hodosy J et al: Vectors and delivery systems in gene therapy. Med Sci Monit, 2005; 11(4): RA110-21
30. Fischer U, Steffens S, Frank S et al: Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene, 2005; 24: 1231-43
31. Kurozumi K, Tamiya T, Ono Y et al: Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol, 2004; 66: 117-27
32. Kim R, Tanabe K, Inoue H, Toge T: Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol, 2002; 20: 549-55
33. Klatzmann D, Valery CA, Bensimon G et al: Phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther, 1998; 9: 2595-604
34. Shand N, Weber F, Mariani L et al: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther, 1999; 10: 2325-35
35. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther, 2000; 20: 2389-2401
36. Dunn IF, Black PM: The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy. Neurosurgery, 2003; 52: 1411-24
37. Colombo F, Barzon L, Franchin E et al: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther, 2005; 12: 835-48
38. Aboody KS, Brown A, Rainov NG et al: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA, 2000; 97: 12846-851